ArticleInflammopharmacology2026
Canagliflozin attenuates Parkinson's disease and is associated with modulation of gut-inflammasome-brain axis in rats.
Article in Inflammopharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Recent evidence links gut dysbiosis and the gut-brain axis to the pathophysiology of Parkinson's disease (PD), which is considered one of the most common neurodegenerative illnesses and is characterized by motor symptoms and a gradual loss of nigral dopaminergic neurons. Canagliflozin (CANA), a sodium-glucose cotransporter-2 inhibitor with emerging anti-inflammatory and antioxidant properties, has recently gained attention for its neuroprotective effects beyond glycemic control. This research aimed to examine the neuroprotective potential of CANA in a rat model of PD, focusing on its potential effect on the gut-inflammasome-brain axis. Rats were treated with rotenone (ROT) (2 mg/kg, subcutaneous) and/or CANA (20 mg/kg, oral) for 30 consecutive days. Behavioral assessment (n = 13), biochemical assays (n = 6), and histological and immunohistochemical analysis (n = 3) were performed. Microbiome profiling (n = 3) using 16S rRNA amplicon sequencing was conducted using three pooled fecal samples/group, with each pool prepared from fecal material collected from three rats and fecal metabolomic profiling (n = 5) was performed to assess microbial metabolites. ROT intoxication caused significant motor impairments, including decreased locomotor activity, poor coordination, and increased catalepsy. Further histological examination demonstrated dopaminergic neuronal loss and α-synuclein aggregation in the substantia nigra and striatum. CANA treatment enhanced motor function, conserved neuronal integrity, and decreased α-synuclein accumulation. Moreover, ROT altered the gut microbiota with selective taxonomic shifts, including enriched abundance of Parabacteroides and Ruminococcaceae with depleted Prevotella-related taxa, in addition to fecal metabolite profile alteration. Consequently, it increased colonic oxidative stress and weakened tight junctions, all of which enhanced LPS translocation. This systemic endotoxemia generated oxidative stress, dyslipidemia, and NF-κB/NLRP3 inflammasome activation. Conversely, CANA restored gut microbial balance and their metabolites, and gut integrity, decreased LPS leakage, and reduced systemic and central oxidative stress and inflammation, preventing inflammasome activation and α-synuclein aggregation. Collectively, these findings suggest that CANA may exert neuroprotective effects in ROT-induced PD associated with modulating the gut-inflammasome-brain axis.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.